The Medical Letter on Drugs and Therapeutics
Testosterone Topical Solution (Axiron) for Hypogonadism
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The Medical Letter recently reviewed a topical gel formulation of testosterone (Fortesta) for treatment of hypogonadism in men.1 A topical testosterone replacement product for application to the axilla, Axiron (Lilly) solution, has now become available for the same indication. This site of application presumably minimizes the risk of transferring the drug to a family member or sexual partner.

PHARMACOKINETICS — Steady state concentrations of testosterone are reached after about 14 days of administration of Axiron and return to pretreatment levels 7-10 days after the last application.

CLINICAL STUDY — In an unpublished 120-day open-label trial summarized in the package insert, 155 hypogonadal men (19-78 years old; median age 53) applied Axiron to the axillary area, starting with a 60-mg dose; the dose could be adjusted ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Testosterone Topical Solution (Axiron) for Hypogonadism
Article code: 1368b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian